



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/890,377	07/27/2001	Alexander Olek	81702	2009
23685	7590	10/08/2003		
KRIEGSMAN & KRIEGSMAN 665 FRANKLIN STREET FRAMINGHAM, MA 01702			EXAMINER CHAKRABARTI, ARUN K	
			ART UNIT	PAPER NUMBER
			1634	

DATE MAILED: 10/08/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.
09/890,377

Applicant(s)
Olek

Examiner
Arun Chakrabarti

Art Unit
1634



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on Aug 26, 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-24 is/are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-24 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
*See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 6) ☒ Other: **Detailed Action**

Art Unit: 1634

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on August 26, 2003 has been entered.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

3. Claims 1-5, and 7-23 are rejected under 35 U.S.C. 103 (a) over Herman et al. (U.S. Patent 6,265,171 B1) (July 24, 2001) in view of Koster (U.S. Patent 5,605,798) (February 25, 1997).

Herman et al teach a method for the identification of cytosine methylation patterns in genomic DNA samples (Abstract) characterized in that:

Art Unit: 1634

a) a genomic DNA sample is treated chemically in such a way that cytosine and 5-methylcytosine react differently and a different base pairing behavior of the two products is obtained in the duplex (Examples 1- 2, and Column 23, line 66 to column 24, line 7 and column 5, line 33 to column 6, line 37 and Claim 1);

b) portions of the thus-treated DNA samples are enzymatically amplified (Example 2, Column 24, lines 4-27 and claim 1);

c) the amplified portions of the thus-treated DNA samples are bound to a surface (in this case polyacrylamide gels) (Figures 1 and 2 and Example 2);

d) a set of probes of different nucleobase sequences, each of which contains the dinucleotide sequence 5'-CpG-3' at least once, are hybridized to the immobilized DNA samples (Figure 1 and Example 2, Column 23, line 27 to column 24, line 3);

e) the non-hybridized probes are separated (inherently in this case by the Southern blot technique) (Example 2 and Figure 1);

Herman et al teach a method, further characterized in that the immobilized complementary oligonucleotide sequences contain modified bases, ribose or backbone units (Example 2, Figures 1 and 2).

Herman et al teach a method, further characterized in that the genomic DNA sample is propagated in b) in the form of several amplified fragments, so that at least 0.01 % of the total genome is amplified (Example 1).

Art Unit: 1634

Herman et al teach a method, further characterized in that the mixture of amplified DNA fragments is bound to a surface, on which a multiple number of different points is arranged, each of which can bind different portions of the amplified DNA sample (Figure 1).

Herman et al teach a method, further characterized in that a set of probes is used in d), which contains the dinucleotide sequence 5'-CpG-3' only once in each probe and the probes otherwise contain either no cytosine or no guanine bases (Column 18, SEQ ID No: 130).

Herman et al teach a method, further characterized in that a bisulfite solution is used together with other reagents for the specific or sufficiently selective conversion of cytosine to uracil (Column 6, lines 7-25 and Example 1, Column 22, lines 24-36).

Herman et al do not teach a method wherein the hybridized probes are analyzed in a mass spectrometer and the position of the probes on the sample holder permits a classification of the hybridizing DNA sample.

Koster teaches a method wherein the hybridized probes are analyzed in a mass spectrometer and the position of the probes on the sample holder permits a classification of the hybridizing DNA sample (Abstract, Examples 1-2, Figures 10-11, Column 4, lines 25-55, and claim 1).

Herman et al do not teach a method, further characterized in that one or more amplified genomic DNA fragments are immobilized in step c) by hybridization with complementary oligonucleotide sequences, which are covalently bound to the surface.

Art Unit: 1634

Koster teaches a method further characterized in that one or more amplified genomic DNA fragments are immobilized in step c) by hybridization with complementary oligonucleotide sequences, which are covalently bound to the surface (Figures 1 and 4 and Example 1 and Claim 4).

Herman et al do not teach a method, further characterized in that a covalent or electrostatic cross-linking of the genomic DNA fragments with the oligonucleotide bound to the surface results after hybridization.

Koster teaches a method, further characterized in that a covalent or electrostatic cross-linking of the genomic DNA fragments with the oligonucleotide bound to the surface results after hybridization (Figures 1-4 and Column 7, line 54 to column 8, line 60).

Herman et al do not teach a method, further characterized in that the hybridized probes are stripped from the immobilized amplified DNA samples before, after or by contact with a matrix.

Koster teaches a method, further characterized in that the hybridized probes are stripped from the immobilized amplified DNA samples before, after or by contact with a matrix (Column 10, line 65 to column 11, line 10).

Herman et al do not teach a method, further characterized in that the probes are nucleic acids, which bear one or more mass tags including charge tags.

Art Unit: 1634

Koster teaches a method, further characterized in that the probes are nucleic acids, which bear one or more mass tags including charge tags (Column 9, line 54 to Column 10, line 15 and Figure 6C).

Herman et al do not teach a method, further characterized in that the probes are modified nucleic acid molecules.

Koster teaches a method, further characterized in that the probes are modified nucleic acid molecules (Column 9, lines 54-67).

Herman et al do not teach a method, further characterized in that the modified nucleic acid molecules are PNAs, or alkylated phosphorothioate nucleic acids.

Koster teaches a method, further characterized in that the modified nucleic acid molecules are PNAs, or alkylated phosphorothioate nucleic acids (Column 9, lines 8-27).

Herman et al do not teach a method, further characterized in that the probes are prepared by combinatorial synthesis.

Koster teaches a method, further characterized in that the probes are prepared by combinatorial synthesis (Column 9, lines 61-67).

Herman et al do not teach a method, further characterized in that different base structural units are labeled in such a way that the each of the probes synthesized from them can be distinguished from their mass in the mass spectrometer.

Art Unit: 1634

Koster teach a method, further characterized in that different base structural units are labeled in such a way that the each of the probes synthesized from them can be distinguished from their mass in the mass spectrometer (Figure 8).

Herman et al do not teach a method, further characterized in that the probes are prepared as sublibraries and these are provided with different mass and/or charge tags.

Koster teach a method, further characterized in that the probes are prepared as sublibraries and these are provided with different mass and/or charge tags (Column 10, lines 1-65).

Herman et al do not teach a method, further characterized in that matrix-assisted laser desorption/ionization mass spectrometry (MALDI) is conducted in f).

Koster teach a method, further characterized in that matrix-assisted laser desorption/ionization mass spectrometry (MALDI) is conducted (Column 10, line 66 to column 11, line 18 and Example 1 and Claims 11, 21, and 39).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the DNA diagnostic based on mass spectrometry of Koster in the method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguish modified methylated and unmethylated nucleic acids of Herman et al. since Koster states, "In addition, because the instant disclosed processes allow the nucleic acid fragments to be identified and detected at the same time by their specific molecular weights (an unambiguous physical standard), the disclosed processes are also much more accurate and reliable than currently available procedures (Column 4, lines 50-55)." An

Art Unit: 1634

ordinary practitioner would have been motivated to combine and substitute the DNA diagnostic based on mass spectrometry of Koster in the method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguish modified methylated and unmethylated nucleic acids of Herman et al. in order to achieve the express advantages, as noted by Koster, of processes which allow the nucleic acid fragments to be identified and detected at the same time by their specific molecular weights (an unambiguous physical standard), and which are also much more accurate and reliable than currently available procedures.

4. Claim 6 is rejected under 35 U.S.C. 103 (a) over Herman et al. (U.S. Patent 6,265,171 B1) (July 24, 2001) in view of Koster (U.S. Patent 5,605,798) (February 25, 1997) further in view of Katouzian-Safadi et al. (Biochimie, (1994), Vol. 76, (2), pages 129-132).

Herman et al. in view of Koster teach the method of claims 1-5, and 7-23 as described above.

Herman et al. in view of Koster do not teach the method, further characterized in that the oligonucleotide bound to the surface contain 5-bromouracil structural units.

Katouzian-Safadi et al. teach the method, further characterized in that the oligonucleotide bound to the surface contain 5-bromouracil structural units (Summary and Results Section).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the oligonucleotide containing 5-bromouracil structural units of Katouzian-Safadi et al. in the mass spectrometric method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguish

Art Unit: 1634

modified methylated and unmethylated nucleic acids of Herman et al in view of Koster since Katouzian-Safadi et al. state, "The substitution of thymine by 5-bromouracil in DNA increases the photocrosslinking yield, and reduces the direct damages to both DNA and protein (Summary, second sentence)." An ordinary practitioner would have been motivated to combine and substitute the oligonucleotide containing 5-bromouracil structural units of Katouzian-Safadi et al. in the mass spectrometric method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguish modified methylated and unmethylated nucleic acids of Herman et al in view of Koster in order to achieve the express advantages, as noted by Katouzian-Safadi et al., of the substitution of thymine by 5-bromouracil in DNA , which increases the photocrosslinking yield, and reduces the direct damages to both DNA and protein.

5. Claim 24 is rejected under 35 U.S.C. 103 (a) over Herman et al. (U.S. Patent 6,265,171 B1) (July 24, 2001) in view of Koster (U.S. Patent 5,605,798) (February 25, 1997) further in view of Stratagene Catalog (1988, Page 39).

Herman et al. in view of Koster expressly teaches the claims 1-5, and 7-23 as described above in detail.

Herman et al. in view of Koster do not teach the motivation to combine all the reagents for identification of cytosine methylation patterns in a genomic DNA samples in the form of a kit.

Stratagene catalog teaches a motivation to combine reagents into kit format (page 39).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine a suitable container, a sample holder for a mass spectrometer,

Art Unit: 1634

all the reagents for identification of cytosine methylation patterns in a genomic DNA samples , as taught by Herman et al. in view of Koster into a kit format as discussed by Stratagene catalog since the Stratagene catalog teaches a motivation for combining reagents of use in an assay into a kit, "Each kit provides two services: 1) a variety of different reagents have been assembled and pre-mixed specifically for a defined set of experiments. Thus one need not purchase gram quantities of 10 different reagents, each of which is needed in only microgram amounts, when beginning a series of experiments. When one considers all of the unused chemicals that typically accumulate in weighing rooms, desiccators, and freezers, one quickly realizes that it is actually far more expensive for a small number of users to prepare most buffer solutions from the basic reagents. Stratagene provides only the quantities you will actually need, premixed and tested. In actuality, the kit format saves money and resources for everyone by dramatically reducing waste. 2) The other service provided in a kit is quality control". (page 39, column 1).

Response to Arguments

6. The request for reconsideration, filed on March 26, 2003, has been considered but does not place the application in condition for allowance because of the following reasons:

A) Applicant argues (page 3, last paragraph to page 4, line 9) that Herman et al reference teaches only the amplification of methylated fragments and does not teach the amplification of both methylated and unmethylated fragments of the instant invention. This argument is not

Art Unit: 1634

persuasive. In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., the amplification of both methylated and unmethylated fragments) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

Moreover, Herman reference clearly teaches the amplification of both methylated and unmethylated fragments (Column 23, line 67 to Column 24, line 3).

B) Applicant also argues (Page 4, last two sentences) that Herman reference does not teach the step(e) of removing any non hybridized probes from the immobilized DNA samples and there would be no reason to hybridize any probes to the MSP amplicates for the purpose of indicating methylation and there would be no reason to remove any non-hybridized probes. This argument is not persuasive. Herman clearly and inherently teaches the separation of non-hybridized probes in the Southern blot technique (Example 2 and Figure 1). Moreover, it is well known to an ordinary practitioner skilled in the art that in any hybridization reaction (no matter how specific the target sample is), there is always a molar excess of unhybridized probes, which must be removed by washing and other means to reduce the background signal of hybridization.

C) Applicant also argues (Page 5, first two lines and page 6, line 3 of third paragraph, and page 8, line 3) that each references individually does not teach all the elements of the claimed invention. This argument is not persuasive. In response to applicant's arguments against the

Art Unit: 1634

references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

D) Applicant also argues (Page 5, lines 3-4 and page 6, lines 5-9 of third paragraph, and page 8, lines 4-8) that there is no motivation to combine the references. This argument is not persuasive, especially in the presence of strong motivation provided by Koster since Koster states, "In addition, because the instant disclosed processes allow the nucleic acid fragments to be identified and detected at the same time by their specific molecular weights (an unambiguous physical standard), the disclosed processes are also much more accurate and reliable than currently available procedure (Column 4, lines 50-55)". Similar logic is applicable to other combinatory references.

In view of the response to arguments, all previous 103(a) rejections are hereby properly maintained.

Conclusion

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D., whose telephone number is (703) 306-5818. The examiner can normally be reached on 7:00 AM-4:30 PM from Monday to Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

Art Unit: 1634


supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-7401. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group analyst Chantae Dessau whose telephone number is (703) 605-1237.


ARUN K. CHAKRABARTI
PATENT EXAMINER

Arun Chakrabarti,

Patent Examiner,

September 25, 2003


GARY BENZION, PH.D
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1800